RE:New MD&A and other sedar "Within the xB3 program, management intends to advance preclinical development of the xB3-TZM program (001 in Brain Metastasis), key development milestones and current target dates for completion (calendar year) include: initiation of manufacturing (Q1 of 2018), request FDA Type B (pre-IND) meeting (Q3 of 2018), initiation of toxicology program (Q2 of 2019) and begin our first-in-man Ph 1 /2 clinical study (Q4 of 2019). The company also intends to fund further work on its other preclinical pipeline programs: the 002 program in Glioblastoma, the company plans to complete preclinical proof-of-concept (POC) (Q3 of 2018), initiate manufacturing (Q4 of 2018) and initiate toxicology studies (Q4 of 2019). For the 007 program in neurodegeneration, the company will plan to complete preclinical POC (Q4 of 2018) and initiate manufacturing (Q1 of 2019)."
Looks like 2020 might be the year for BTI.